When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AIMT - Aimmune Therapeutics Could Achieve Regulatory Firsts With Peanut Allergy Treatment
Aimmune Therapeutics Inc.
Aimmune (AIMT) had very good news on Monday, after it had announced a successful phase 3 study from Europe dealing with peanut allergy. The success of this study will allow for a regulatory filing in the European Union in the coming months. The biotech is also awaiting for its review of the BLA application that was submitted to the FDA as well. With the ability to gain regulatory approvals for AR101 in both territories in the coming year, I expect that the biotech should be trading higher based on these catalysts.